Molecular Health starts market entry and product distribution in Eastern Europe - Molecular HealthMolecular Health

Newsroom

All news

Molecular Health starts market entry and product distribution in Eastern Europe

As it gains a foothold in European markets, Molecular Health (MH) has started distributing the latest development of its flagship product, Molecular Health Guide (MH Guide), in the Ukraine, Moldova and Romania. This medical application supports oncologists on delivering the right drug to the right patient at the right time – the very essence of personalized medicine.

 

Molecular Health, pioneer in data- and analytics-driven precision medicine, expands its efforts to establish collaborations in Eastern European countries. In cooperation with its partner and distributor, Chisinau-based Oncogene SRL (www.oncogene.eu), Molecular Health starts to bring its technology (Dataome) and products also to hospitals in the Ukraine, Moldova and Romania.

 

First stop of MH’s roadshow was Kyiv. In front of 25 oncologists MH experts and OncoGene delegates presented MH Guide, a treatment decision-support tool which is registered as in-vitro diagnostic medical device (IVD) in Europe and is CE-compliant with European regulations. MH Guide includes all steps of the clinical genomics workflow in oncology, from raw sequencing data to generating an interactive, editable medical report. It is the first product of its kind in Germany to be reimbursed by public health insurances.

 

“Strategic partnerships and collaborations are essential for us to grow, as our regional partners enable us to efficiently bring our products to market,” says Stephan Hettich, Head of Business Development & Sales at Molecular Health, speaking of MH Guide.

 

Next stop was Chisinau, Moldova, before a third opportunity will be taken in March 2020 in Bucharest where MH and Oncogene will exhibit and sponsor the 1st International Congress for Gynecologic Oncology (https://www.icgo2020.eu/).

 

In future, precise and individual approaches in oncological therapy will play an even more important role in diagnosing and treating patients. As tumors become increasingly better genetically characterized and understood, patients very likely will benefit from such highly targeted approaches prior to treatment.